gene_therapy

Genprex Links TUSC2 Gene Therapy to Cell Repair Pathways in 11 Patients

Image
Genprex Links TUSC2 Gene Therapy to Cell Repair Pathways in 11 Patients

Austin, Texas – November 05, 2026 -- Genprex (NASDAQ: GNPX) reported that whole-blood analysis of 11 lung cancer patients treated with its gene therapy REQORSA (quaratusugene ozeplasmid) showed a shift toward mitochondrial adaptation, autophagy and protein quality control 24 hours after infusion. The company presented the findings at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting, held November 4-7 in National Harbor, Maryland.

Blood samples from two REQORSA trials show a two-phase response

The patients were enrolled in two clinical trials evaluating REQORSA. Researchers collected whole-blood transcriptomes before treatment and at 5 and 24 hours after intravenous administration. They compared the 0-5, 5-24 and 0-24 hour intervals to separate the acute response to delivery from the sustained cellular-remodeling program.

Nanoscope Fields Four Executives at Advanced Therapies USA 2026

Image
Nanoscope Fields Four Executives at Advanced Therapies USA 2026

DALLAS – October 29, 2026 -- Nanoscope Therapeutics will field four executives across six sessions at Advanced Therapies USA 2026 in Boston on November 4-5, as its optogenetic gene therapy MOGENRY (sonpiretigene isteparvovec; MCO-010) awaits decisions from the U.S. FDA and Japan's PMDA. The conference, held at the Hynes Convention Center, brings together cell and gene therapy developers, manufacturers, investors and commercial leaders.

Genprex Takes TUSC2 Aging Research to GSA 2026 Poster Session

Image
Genprex Takes TUSC2 Aging Research to GSA 2026 Poster Session

AUSTIN – October 29, 2026 -- Genprex (NASDAQ: GNPX) will present research on the TUSC2 gene, the therapeutic payload of its lead lung cancer candidate REQORSA, in mitochondrial biology and cellular aging at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting, widening the scientific case for the asset beyond oncology.

Poster scheduled for Nov. 4 in National Harbor, Maryland

The poster, titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program," will run in Late Breaking Poster Session I from 6:00 to 7:15 p.m. ET at the Gaylord National Resort & Convention Center, Exhibit Hall C-D. Mark S. Berger, MD, Genprex's Chief Medical Officer, will present under Abstract ID 2489375. The meeting runs Nov. 4-7, 2026.

Solid Biosciences Doses First Patient in FALCON Gene Therapy Trial

Global – October 27, 2026 -- Solid Biosciences has dosed the first participant in FALCON, a Phase 1b trial of SGT-212, its investigational gene therapy for Friedreich's ataxia (FA), and expects to release an initial data update in the second half of 2026, subject to patient enrollment.

FALCON tests a dual-route gene therapy in adults aged 18-40

FALCON is an open-label, dose-finding study designed to evaluate the safety and tolerability of SGT-212 in people aged 18-40 living with FA. Solid describes the approach as novel and first-in-class. It is the first-in-human study of SGT-212.

Intradentate nucleus infusion precedes intravenous delivery

Each participant receives an intradentate nucleus (IDN) infusion targeting the cerebellar dentate nuclei, followed by an intravenous (IV) infusion. Solid says the dual routes are intended to address the neurologic, cardiac and systemic manifestations of FA.

Base-Editing Therapy tBE Shows Durable Remission Across Ethnic Groups

Image
Base-Editing Therapy tBE Shows Durable Remission Across Ethnic Groups

Shanghai – September 13, 2026 -- CorrectSequence Therapeutics (Correctseq) reported that its transformer Base Editor (tBE) platform achieved sustained transfusion independence or elimination of vaso-occlusive crises (VOCs) in four new patients from Nigeria, Laos, Malaysia and Pakistan, extending clinical validation beyond the Chinese cohort where five patients previously achieved full transfusion independence.

Study published in Cell Stem Cell confirms cross-genetic efficacy of CS-101/CS-206

The peer-reviewed paper, published online September 13, 2026, details results from one sickle cell disease (SCD) patient and three transfusion-dependent β-thalassemia (TDT) patients treated with CS-101/CS-206. All four achieved rapid hematopoietic reconstitution, sustained high-level pancellular fetal hemoglobin (HbF) expression, and no detectable off-target edits or product-related adverse events.

REGENXBIO to Present at Baird, Morgan Stanley Healthcare Conferences

Image
REGENXBIO to Present at Baird, Morgan Stanley Healthcare Conferences

Rockville, Maryland – September 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.

REGENXBIO confirms back-to-back fireside chats on September 15 and 16

The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.